Search - tctmd.com

Displaying 741 - 760 of 900

Sort: Relevancy | Date

Presentation

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Presenter: Rossella Marcucci

December 12, 2012

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation

Bivalirudin for Primary PCI

Presenter: B. Hibbert

November 26, 2012

Presentation

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Presenter: Eric L. Eisenstein

November 19, 2012

Presentation

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Presenter: C. Quintavalle

November 15, 2012

Presentation

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Presenter: A. Sachdeva

November 13, 2012

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington

October 25, 2012

Presentation TCT 2012

Part 1: Oral Anticoagulants

Presenter: Christopher Granger

October 25, 2012

Presentation TCT 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presenter: Michael Love

October 25, 2012

Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone

October 25, 2012

Presentation TCT 2012

Ticagrelor Update: PLATO: Recent Analyses

Presenter: Robert Harrington

October 24, 2012

Presentation TCT 2012

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Presenter: C. Michael Gibson

October 24, 2012

Presentation TCT 2012

Prasugrel Update: TRILOGY

Presenter: E. Magnus Ohman

October 24, 2012

Presentation TCT 2012

Prasugrel Is the Gold Standard!

Presenter: Matthew Price

October 24, 2012

Presentation TCT 2012

GP IIb/IIIa Inhibition: New Studies, New Insights

Presenter: David Moliterno

October 24, 2012

Presentation TCT 2012

Factor IXa Inhibition (Aptamer) Update

Presenter: Roxana Mehran

October 24, 2012

Advertisement

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Bivalirudin for Primary PCI

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Part 2: Antiplatelet Agents

Part 1: Oral Anticoagulants

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Ticagrelor Update: PLATO: Recent Analyses

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Prasugrel Update: TRILOGY

Prasugrel Is the Gold Standard!

GP IIb/IIIa Inhibition: New Studies, New Insights

Factor IXa Inhibition (Aptamer) Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content